醫美板塊持續下挫 愛美客跌超8% 科技日報揭露美白針危害
格隆匯8月20日丨醫美板塊持續下挫,愛美客跌超8%,貝泰妮跌超7%,華熙生物、國際醫學跌超6%,愛爾眼科、復星醫藥、冠昊生物、華東醫藥等紛紛跟跌。昨日,科技日報刊文痛批美白針,揭露了美白針的真相,也指明瞭快速變白背後的健康代價。據專家介紹,美白針的核心成分就3種,也只有它們在發揮作用:還原型谷胱甘肽、氨甲環酸(傳明酸)、維生素C。目前這些美白針中所含成分沒有獲得我國藥監局批准的適應症,長期使用會出現一些不良反應,甚至發生嚴重的併發症。值得注意的是,現在國內並沒有正規上市的美白針,都是“三無”產品。而美白針的利潤很高,注射用的還原型谷胱甘肽、氨甲環酸、維生素C等藥劑本身成本並不高,但是在不少美容機構裏, 注射一次美白針就要花費千元左右。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.